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AIM
The aim of this study was to study potential cytochrome P450 (CYP) induction by dicloxacillin.
METHODS
We performed an open-label, randomized, two-phase, ﬁve-drug clinical pharmacokinetic cocktail crossover study in 12 healthy
men with and without pretreatment with 1 g dicloxacillin three times daily for 10 days. Plasma and urine were collected over 24 h
and the concentration of all ﬁve drugs and their primary metabolites was determined using a liquid chromatography coupled to
triple quadrupole mass spectrometry method. Cryopreserved primary human hepatocytes were exposed to dicloxacillin for 48 h
and changes in gene expression and the activity of CYP3A4, CYP2C9, CYP2B6 and CYP1A2 were investigated. The activation of
nuclear receptors by dicloxacillin was assessed using luciferase assays.
RESULTS
A total of 10 days of treatment with dicloxacillin resulted in a clinically and statistically signiﬁcant reduction in the area under the
plasma concentration–time curve from 0 to 24 h for omeprazole (CYP2C19) {geometric mean ratio [GMR] [95% conﬁdence
interval (CI)]: 0.33 [0.24, 0.45]}, tolbutamide (CYP2C9) [GMR (95% CI): 0.73 (0.65, 0.81)] and midazolam (CYP3A4) [GMR (95%
CI): 0.54 (0.41, 0.72)]. Additionally, other relevant pharmacokinetic parameters were affected, indicating the induction of
CYP2C- and CYP3A4-mediated metabolism by dicloxacillin. Investigations in primary hepatocytes showed a statistically signiﬁ-
cant dose-dependent increase in CYP expression and activity by dicloxacillin, caused by activation of the pregnane X receptor.
CONCLUSIONS
Dicloxacillin is an inducer of CYP2C- and CYP3A-mediated drug metabolism, and we recommend caution when prescribing
dicloxacillin to users of drugs with a narrow therapeutic window.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Dicloxacillin is known to reduce the therapeutic efﬁcacy of warfarin treatment but the mechanism is unknown.
WHAT THIS STUDY ADDS
• This study shows that dicloxacillin is a clinically relevant inducer of cytochrome P450 (CYP2C9)-, CYP2C19- and
CYP3A4-mediated expression and activity. In vitro results show that this is caused by pregnane X receptor activation,
leading to increased expression and activity of these enzymes. Clinicians prescribing dicloxacillin should be aware that
dicloxacillin induces CYP2C9-, CYP2C19- and CYP3A4-mediated metabolism.
Introduction
Dicloxacillin belongs to the group of narrow-spectrum
isoxazolyl beta-lactam penicillins (Figure 1) and is primarily
used for skin-, soft tissue-, or bone infections caused by
Staphylococcus aureus [1]. As dicloxacillin exhibits strong
time-dependent antibacterial activity, the time above the
minimal inhibitory concentration (0.125 μg ml–1) is crucial
for its clinical effect [2]. Due to the short elimination half-life
of dicloxacillin (60–90 min after oral ingestion [3, 4]),
administration every 6–8 h is necessary to sustain sufﬁcient
bactericidal concentrations. Following an oral dose of
500 mg dicloxacillin administered four times daily, plasma
concentrations ﬂuctuate from 2 μM, the minimum
plasma concentration (Cmin), to 57 μM, the maximum plasma
concentration (Cmax) [4]. Data on the utilization patterns of
beta-lactamase-resistant penicillins in general, and
dicloxacillin speciﬁcally, are scarce [5]. Dicloxacillin is the dom-
inant choice of isoxazolyl penicillin in both Denmark and
Norway, with annual prevalences of 25 [6] and 20 (www.
reseptregisteret.no) per 1000 inhabitants, respectively.
In humans, dicloxacillin is primarily excreted unchanged
renally, but also metabolized to some extent to the 5-hydroxy
metabolite [7], although it is unclear which cytochrome P450
(CYP) enzymes are involved in the metabolism. Dicloxacillin
is a substrate of P-glycoprotein (P-gp, ABCB1) [8], and
concomitant intake of rifampicin leads to lower plasma
concentrations of dicloxacillin, accompanied by increased
plasma concentrations of the 5-hydroxy metabolite. This is
likely to be caused by a combination of induction of CYP
enzymes relevant for dicloxacillin metabolism and induction
of intestinal P-gp [9].
Several case reports have described that initiation of
either dicloxacillin or cloxacillin treatment leads to a
decreased international normalized ratio (INR), a proxy
biomarker of clinical efﬁcacy, during treatment with the vita-
min K antagonist, warfarin [10–13]. In a recent observational
study of 236 patients, we conﬁrmed that initiation of
dicloxacillin treatment resulted in markedly decreased INR
values during warfarin therapy [14], leading to subtherapeu-
tic INR levels in 60% of the treated patients. Additional case
reports have described that initiation of treatment with
another isoxazolyl penicillin, ﬂucloxacillin, resulted in
decreased plasma levels of voriconazole [15] and quinidine
[16]. The mechanistic basis for drug–drug interactions with
isoxazolyl penicillins is unknown. Sparse in vitro data have
indicated that dicloxacillin activates pregnane X receptor
(PXR), causing increased CYP3A4-mediated testosterone
metabolism in human hepatocytes [17] and induction of
CYP2C9 [18]. PXR activation leading to upregulation of CYP
enzymes and subsequent increased metabolism may provide
an explanation for the above-mentioned drug–drug interac-
tions, but this has not been conﬁrmed in clinical pharmaco-
kinetic studies.
The objective of the present study was to determine the
effect of treatment with a clinically relevant treatment course
of dicloxacillin on the metabolic capacity of CYP3A4,
CYP2C9, CYP2C19, CYP1A2 and CYP2D6 in healthy
volunteers. We investigated the underlying mechanism
in vitro using cryopreserved human hepatocytes to assess
changes in the expression and activity of CYP enzymes and
nuclear receptor activation by dicloxacillin.
Methods
Clinical study
The study was designed as an open-label, randomized,
two-phase, ﬁve-drug clinical pharmacokinetic cocktail study
to assess the potential of dicloxacillin to induce CYP
enzymes. We used a validated and previously used ﬁve-drug
cocktail [19–21] to assess metabolic capacity of major
drug-metabolizing enzymes (CYP2C9: tolbutamide; CYP3A4:
midazolam; CYP2C19: omeprazole; CYP1A2: caffeine; and
CYP2D6: dextromethorphan).
Pharmacokinetic cocktail studies are used to assess the
metabolic capacity of CYP3A4, CYP2C19, CYP2D6 and
CYP1A2 simultaneously by pharmacokinetic assessment of
CYP-speciﬁc probes. We used a modiﬁed Cooperstown
cocktail (midazolam, omeprazole, dextromethorphan and
caffeine) [22]. As (S)-warfarin (the most pharmacologically
active isomer of racemic warfarin) is metabolized by CYP2C9,
we added tolbutamide, a well-validated substrate and
Figure 1
The chemical structure of isoxazolyl penicillins
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biomarker for CYP2C9 metabolism [23], to the cocktail. This
combination of biomarker drugs has previously been vali-
dated [19] and used to evaluate the changes in drug
metabolism caused by drug–drug interactions [20, 21].
Studymedication and dose. Tolbutamide (Arcosal® one 500mg
tablet, Meda AS, Allerød, Denmark), dextromethorphan
(Dexofan® one 30 mg tablet, Takeda Pharma, Taastrup,
Denmark), omeprazole (Omestad® one 20 mg enteric
capsule, Stada Nordic ApS, Herlev, Denmark) and caffeine
(two 100 mg caffeine tablets produced at Glostrup Hospital
Pharmacy, Copenhagen, Denmark) were all administered
orally. Midazolam was administered as a buccal solution of
2.5 mg (Buccolam®, Shire Sweden AB, Stockholm, Sweden)
between the cheek and the gums slowly, at least 3 min after
the oral drugs were ingested. Dicloxacillin was administered
as two 500 mg capsules (Dicloxacillin ‘Alternova’®, Alternova
A/S, Odense, Denmark) three times daily for 10 days; at least
1 h before or at least 2 h after a meal. This is the dicloxacillin
dosage regimen for the treatment of Staphylococcus aureus in
Denmark, as recommended by the Danish Physicians’ Desk
Reference (www.pro.medicin.dk).
Design and study criteria. Twelve healthy men were
recruited for this two-phase study and ingested the ﬁve-
drug cocktail in both phases after 12 h of fasting. Women
were excluded owing to a putative clinically relevant drug–
drug interaction between oral contraceptives and
dicloxacillin. In phase A, no concomitant drugs were used.
In phase B, dicloxacillin was administered as 1 g three
times daily for 10 days prior to the study day. On the
morning of day 11, the ﬁve-drug cocktail was ingested as in
phase A. There was a washout period of at least 6 weeks
between the two phases (Figure 2). Plasma samples were
drawn at 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h. Urine was
collected at 0–12 h and 12–24 h for determination of
metabolites. The participants were given a meal 3 h after
ingesting the drugs. The inclusion criteria for the study
were: nonsmoking healthy men aged 18–55 years,
body mass index (BMI) 18.5–29.9 kg m–2 and estimated
glomerular ﬁltration rate (eGFR), alanine transaminase
(ALAT), bilirubin, haemoglobin and glycosylated
haemoglobin A1c (HbA1c) within the respective reference
ranges. Exclusion criteria for the study were: known
allergies to any of the used drugs; known penicillin allergy
or type 1 reaction to cephalosporines; known allergy to
sulphonylureas; intake of prescription drugs, over-the-
counter drugs, herbal medicines or supplements known to
affect drug pharmacokinetics; chronic or daily alcohol
abuse; and participation in other intervention trials.
Health status and use of drugs were assessed by answers to
the following ﬁve questions: Are you healthy? Do you
suffer from any chronic diseases? Do you ingest drugs on a
daily basis? Do you occasionally use prescription drugs?
Do you use any over-the-counter or herbal medicines
or supplements? A data manager performed block
randomization using Sealed Envelope, which is freely
available at www.sealedenvelope.com. The list was then
made accessible to trial investigators using REDCap [24].
Study approval. The clinical study was conducted in
accordance with the Helsinki Declaration and Good Clinical
Practice (GCP) and monitored by the GCP Unit, Odense
University Hospital, Odense, Denmark. The study protocol
was approved by the Danish Medicines Agency (identiﬁer
2 016 043 478), registered in the EudraCT database
(identiﬁer 2016–001334-10) and the Regional Scientiﬁc
Ethical Committee of Southern Denmark (identiﬁer
S-20160073), and all subjects consented to participate in the
study. The trial was registered at http://www.clinicaltrials.
gov (identiﬁer NCT02983890).
Determination of drugs and their metabolites in plasma
and urine. The analysis for the ﬁve probe drugs for
major CYP isoenzymes (CYP1A2, CYP2C9, CYP2C19,
CYP2D6 and CYP3A4) was performed in plasma
and urine samples. The samples were analysed for
caffeine, paraxanthine, omeprazole, 5-hydroxyomeprazole,
tolbutamide, 4-hydroxytolbutamide, dextromethorphan,
dextrorphan, midazolam and α-hydroxymidazolam. The
analysis of plasma was performed according to the
method described by Wohlfarth et al. [19] with minor
modiﬁcation, using isotope dilution, solid-phase extraction
(SPE) and liquid chromatography coupled to triple
quadrupole mass spectrometry (LC–MS/MS). Urine samples
were deglucuronidated prior to the addition of the isotope-
labelled internal standard and dilution with the mobile
phase before injection into the LC–MS/MS system.
Analysis of omeprazole and its metabolite in urine was
performed prior to the deglucuronidation procedure as
Figure 2
Flowchart of clinical study with 12 healthy men. All individuals completed the study
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these compounds are not stable during this acidic process.
The LC–MS/MS system consisted of a Dionex Ultimate
3000 UHPLC system equipped with an EQuan MAX
autosampler unit; a Dionex Ultimate 3000 RS column
compartment; and an Ultimate 3000 RS Pump, connected
to a TSQ Quantiva Triple Quadrupole Mass Spectrometer,
with heated-electrospray ionization operated in positive
mode (Thermo Scientiﬁc, San José, CA, USA). Data
acquisition was performed in single reaction monitoring
(SRM) mode, with transitions optimized for all the
compounds. Calibration curves, blanks and quality control
samples were included in each batch of samples analysed.
The method was linear, with r > 0.9992. The between-day
reproducibility and intra-day repeatability was <5.2% and
<5.5%, respectively, for all compounds. The accuracy reported
as bias ranged from 2.6% to 1.8%. The limit of detection
ranged from 0.05 ng ml–1 to 0.75 ng ml–1, and the limit of
quantiﬁcation ranged from 0.1 ng ml–1 to 1.5 ng ml–1 [19].
Genotyping. Brieﬂy, a Maxwell™ 16 Blood DNA kit (Promega,
Madison, WI, USA) was used to isolate DNA from whole-blood
samples according to the manufacturer’s protocol. Single
nucleotide polymorphisms [CYP2C9*2/*3, CYP2C19*2/*3/*17
and CYP2D6*3/*4/*6/copy number variation (*N), (Table S1)]
were genotyped using predesigned TaqMan SNP genotyping
assays on a StepOne Plus real-time instrument (Applied
Biosystems, Foster City, CA, USA) according to the
manufacturer’s protocol.
Statistics and pharmacokinetic analysis. The primary
endpoint of the study was the difference in the area
under the plasma concentration–time curve from 0 to 24 h
(AUC0–24 h) for tolbutamide with and without dicloxacillin.
To detect a difference of ≥25% in tolbutamide AUC0–24 h
with 80% power, a two-sided signiﬁcance level of 5% and,
allowing a dropout rate of 20%, a total of 12 healthy
individuals were required. Demographic data are shown as
medians with interquartile ranges (IQR; 25th–75th
percentiles). Pharmacokinetic endpoints are presented as
medians with IQR and geometric mean ratios, with
95% conﬁdence intervals. Statistical signiﬁcance was
determined using paired t-tests and accepted at P < 0.05.
Pharmacokinetic data were analysed by noncompartmental
analysis using the R package NCAPPC [25]. The AUC0-t was
estimated using the linear-up/logarithmic-down method.
The formation clearance (CLf) and renal clearance (CLR)
were estimated using the following equations:
CLf ¼ Amount of metabolite in urine0–t=AUC of substrate0–t
CLR ¼ Amount of substrate in urine0–t=AUC of substrate0–t
Due to the short elimination half-lives of omeprazole and
midazolam, 0–12 h CLf and CLR were calculated, while 0–24 h
values were calculated for caffeine, dextromethorphan and
tolbutamide.
In vitro
Cell culture. The methods for cell culture, gene expression
and CYP activities in human hepatocytes have been
described in detail previously [26]. Brieﬂy, cryopreserved
human hepatocytes [male lots: HU1765 (ThermoFisher
catalogue #HMCPIS (ThermoFisher Scientiﬁc, Waltham,
MA, USA)), HUM4034 (Triangle Research Laboratories
catalogue #HUCPI (Morrisville, NC, USA)); female lots:
HH1057 (In Vitro ADMET Laboratories (Columbia, MD, USA)
catalogue #82006), OII (Bioreclamation IVT (Westbury, NY,
USA) catalogue #F00995-P)] were plated at 70 000 cells/well
in collagen-coated 96-well plates in CHRM™ medium
(ThermoFisher Scientiﬁc, Waltham, MA, USA) to obtain a
monolayer of cells. After 4 h of incubation, the cells were
overlaid with cold incubation media containing 0.35 mg ml–1
GelTrex® (ThermoFisher Scientiﬁc, Waltham, MA, USA).
The following day, the medium was replaced with fresh
medium and incubated for another 24 h. On day 3, the cells
were incubated for 48 h with dicloxacillin, ﬂucloxacillin,
rifampicin (PXR agonist, CYP3A and CYPC regulation),
phenobarbital [constitutive androstane receptor (CAR)
agonist, CYP2B6 regulation] or 3-methylcholanthrene [-aryl
hydrocarbon receptor (AhR) agonist, CYP1A regulation]
in increasing concentrations or with vehicle [0.1% dimethyl
sulfoxide (DMSO)].
Gene expression and activity of CYP enzymes. Changes in gene
expression for a panel of drug-metabolizing enzymes and
several transporters were determined using a QuantiGene
Plex 2.0 assay kit (ThermoFisher Scientiﬁc, Waltham, MA,
USA). The activity of relevant CYP enzymes was assessed
using well-validated probe drugs (CYP3A4: 100 μM
testosterone; CYP2C9: 100 μM diclofenac; CYP2B6: 500 μM
bupropion; and CYP1A2: 100 μM phenacetin). After
incubation with dicloxacillin, ﬂucloxacillin and positive
controls, hepatocytes were incubated with probe drugs for
90 min and metabolite levels were measured using an
established LC–MS/MS method [27]. Activity and gene
expression values are presented as activity/expression
relative to vehicle (0.1% DMSO).
Nuclear receptor activity. Activation of PXR, CAR and AhR
was assessed by Puracyp (Carlsbad, CA, USA), as previously
described [28, 29]. Brieﬂy, a HepG2-derived cell line stably
transfected with nuclear receptors and corresponding
response elements were seeded in 96-well plates. After 24 h,
the cells were exposed to six different concentrations of
dicloxacillin and ﬂucloxacillin, and then incubated
for another 24 h. Receptor activity was assessed using
ONE-Glo® luciferase assays (Promega Corporation,
Madison, WI, USA), and cytotoxicity was assessed using the
CellTiter-Fluor® assay (Promega Corporation). Rifampicin,
6-(4-Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde
O-(3,4-dichlorobenzyl)oxime (CITCO) and3-methylcholanthrene
were used as positive controls for PXR, CAR and AhR activation,
respectively. Data for nuclear receptor activity were adjusted
for viability and expressed relative to vehicle control.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY [30], and are permanently archived in the
Concise Guide to PHARMACOLOGY 2015/16 [31–33].
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Results
Clinical study
The study was an open, two-phase, randomized, clinical
pharmacokinetic crossover study in 12 healthy men
(Figure 2). The median age was 22 years (IQR 21–24; range
21–29 years) and the median BMI was 24.3 kg m–2 (IQR
23.3–25.6; range 20.4–28.7). A ﬁve-drug cocktail of midazo-
lam (CYP3A4) (2.5 mg buccal), tolbutamide (CYP2C9)
(500 mg tablet), omeprazole (CYP2C19) (20 mg enteric
capsule), caffeine (CYP1A2) (two 100 mg tablets) and dextro-
methorphan (CYP2D6) (30 mg tablet) was administered
before and after 10 days of treatment with 1 g dicloxacillin
three times daily. The sequence of study phases was
randomized to avoid period effects, and a washout period of
at least 6 weeks was required between the two phases, to
avoid carryover effects. Two subjects suffered nausea and diz-
ziness following multiple attempts at insertion of the cubital
vein cannula. Following treatment with dicloxacillin, one
subject described dyspepsia and stomach pain, and one
subject had an erythematous rash on the extremities, all of
which are well-described adverse reactions [34]. All adverse
reactions were transient and not deemed serious.
Pharmacogenetics
Subjects were genotyped for the most common functional
genetic variants in CYP2D6 (*3; *4; *6 and copy number
variation *N), CYP2C9 (*2; *3) and CYP2C19 (*2; *3; *17) after
conclusion of the study. Genotypes for the 12 subjects are
shown in Table S1. One CYP2D6 poor metabolizer, two
CYP2C19 ultrarapid metabolizers and two CYP2C9 poor
metabolizers were included in the study. The main analysis
presented here is intent-to-treat, including all subjects, re-
gardless of genotype. A sensitivity analysis which excluded
individuals carrying altered function variants did not affect
the conclusions of the study (Table S2).
Pharmacokinetics
AUC0–24 h, Cmax, elimination half-life (T½) and CLf for the
main metabolite of all ﬁve probe drugs with and
without dicloxacillin exposure are shown in Table 1 and
concentration–time curves for the ﬁve probes with and with-
out dicloxacillin are depicted in Figure 3. Individual values of
CLf with and without dicloxacillin exposure are shown in
Figure 4. Detailed pharmacokinetic results are shown in Table
S3, which contains pharmacokinetic data for all probe drugs
and their metabolites. Full pharmacokinetic proﬁles were
available for all 12 individuals, for all drugs except caffeine;
two subjects were excluded from the caffeine analysis as they
violated the protocol by ingesting caffeine during the trial.
With concomitant dicloxacillin treatment, the AUC0–24 h of
all probe drugs was signiﬁcantly reduced, without changes in
CLR (Table 1, Table S3, Figure 3). Tolbutamide AUC0–24 h and
Cmax were reduced by 27% and 7%, respectively, driven
by increased formation of the 4-hydroxytolbutamide metabo-
lite, as reﬂected in a 64% increase in the CLf of the metabolite
Table 1
Noncompartmental pharmacokinetic analysis of probes
Drug Parameter Without dicloxacillin With dicloxacillin GMR (95% CI)
Tolbutamide
(CYP2C9)
AUC0–24 h (ng*h ml
–1) 621 507 (505775–744 162) 404 391 (355015–582 480) 0.73 (0.65, 0.81)
Cmax (ng ml
–1) 51 706 (48907–54 467) 49 130 (47739–52 615) 0.93 (0.87, 1.00)
T½ (h) 9.0 (6.8–13.5) 6.1 (4.8–9.2) 0.72 (0.65, 0.79)
CLf (l h
–1) 0.06 (0.05–0.12) 0.12 (0.09–0.16) 1.64 (1.44, 1.87)
Omeprazole
(CYP2C19)
AUC0–24 h (ng*h ml
–1) 228.4 (188.8–343.7) 80.2 (63.7–101.1) 0.33 (0.24, 0.45)
Cmax (ng ml
–1) 149.5 (105.5–242.2) 58.0 (42.8–77.3) 0.40 (0.25, 0.66)
T½ (h) 1.5 (1.2–3.5) 3.5 (2.2–5.6) 1.62 (0.71, 3.71)
CLf (l h
–1) 1.9 (0.5–4.3) 3.7 (1.7–7.5) 2.01 (0.69, 5.89)
Midazolam
(CYP3A4)
AUC0–24 h (ng*h ml
–1) 37.4 (31.9–44.0) 23.5 (14.6–29.1) 0.54 (0.41, 0.72)
Cmax (ng ml
–1) 12.0 (9.6–13.7) 8.9 (6.2–12.5) 0.77 (0.59, 1.01)
T½ (h) 7.6 (5.5–9.9) 7.7 (6.3–8.5) 1.08 (0.87, 1.33)
CLf (l h
–1) 38 (31–43) 67 (42–80) 1.59 (1.23, 2.06)
Dextromethorphan
(CYP2D6)
AUC0–24 h (ng*h ml
–1) 12.0 (5.4–24.5) 4.5 (2.7–11.2) 0.52 (0.32, 0.83)
Cmax (ng ml
–1) 1.15 (0.74–2.5) 0.76 (0.65–0.95) 0.69 (0.54, 0.89)
T½ (h) (n = 6) 13.9 (12.4–18.2) 21.4 (11.8–25.1) 1.25 (0.53, 2.93)
CLf (l h
–1) 771 (275–1927) 1561 (483–2800) 1.57 (0.97, 2.55)
Caffeinea
(CYP1A2)
AUC0–24 h (ng*h ml
–1) 22 447 (20671–27 837) 19 358 (14563–23 851) 0.81 (0.71, 0.92)
Cmax (ng m
–1l) 3185 (2936–3890) 3213 (2838–3422) 0.92 (0.81, 1.04)
T½ (h) 4.5 (3.9–4.6) 4.0 (3.0–4.8) 0.88 (0.79, 0.99)
CLf (1 h
–1) 0.45 (0.33–0.50) 0.47 (0.38–0.62) 1.17 (0.98, 1.39)
Data are shown as medians with interquartile ranges. AUC0–24 h, area under the plasma concentration–time curve from 0 to 24 h; CI, conﬁdence
interval; Cmax, maximum plasma concentration; CLf: formation clearance of the main metabolite; CYP, cytochrome P450; GMR, geometric mean
ratio; T½, half-life
aPharmacokinetic data for only 10 individuals for caffeine are shown
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(Figure 4). Omeprazole AUC0–24 h and Cmax were 67% and 60%
lower, respectively, with dicloxacillin exposure. Although the
CLf of the CYP2C19-mediated 5-hydroxyomeprazole
metabolite was twice as high with dicloxacillin exposure, this
was not statistically signiﬁcant {P = 0.18; geometric mean
ratio [GMR] [95% conﬁdence interval (CI): 2.01 (0.69, 5.89]}.
Dicloxacillin treatment also led to a 46% reduction in midazo-
lam AUC0–24 h, attributed to increased CYP3A4 metabolism,
as reﬂected by a 59% increase in the CLf of the -
-hydroxymidazolam metabolite. The ratio of the midazolam-
to-metabolite AUC0–24 h increased slightly, with signiﬁcant
imprecision [GMR (95% CI): 1.27 (0.89, 1.80)]. Dicloxacillin
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Figure 3
Plasma concentration–time curves for tolbutamide (A), omeprazole
(B), midazolam (C) caffeine (D) and dextromethorphan (E) with
and without dicloxacillin. Only 10 individuals were included in the
caffeine group owing to a violation of the protocol
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Figure 4
Formation clearance (CLf) for tolbutamide and midazolam with and
without dicloxacillin. CLf was calculated as: Amount of metabolite in
urine0–t/AUC of substrate0–t, where AUC is the area under the plasma
concentration–time curve and t is time. One cytochrome P450
m(CYP) 2D6 poor metabolizer was excluded from the dextromethor-
phan graph, to avoid clustering of the remaining individuals. Two
individuals were excluded from the caffeine analysis owing to
ingestion of caffeine during the study. Dashed lines represent
CYP2C9 poor metabolizers for tolbutamide and CYP2C19 ultrarapid
metabolizers for omeprazole
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also caused minor changes in caffeine pharmacokinetics; caf-
feine AUC0–24 h was 19% lower with dicloxacillin with no
change in CLf, suggesting that the changes in AUC0–24 h were
not caused by increased CYP1A2-mediated paraxanthine me-
tabolism. Dicloxacillin also caused a marked 48% decrease in
dextromethorphan AUC0–24 h.
Human hepatocytes
The effect of dicloxacillin on the expression and activity of
CYP3A4, CYP2C9, CYP2B6 and CYP1A2 was assessed in
cryopreserved hepatocytes from four donors (two male and
two female). Data from all donors are shown in Figure 5,
and individual data from the four donors are shown in
Figures S1–S4. All data are shown relative to the 0.1% DMSO
control, and all mentioned results were statistically signiﬁ-
cant. Dicloxacillin led to dose-dependent upregulation of
CYP3A4, CYP2C9 and CYP2B6, but not CYP1A2 expression,
in all hepatocyte samples (Figure 5A). CYP3A4 mRNA expres-
sion increased 11.0- to 42.0-fold, while CYP2C9 and CYP2B6
mRNA expression increased by 1.7- to 2.7-fold and 2.5- to
2.9-fold, respectively (Figure 5A). Corresponding increases
in enzyme activity were 4.0- to 16.0-fold for CYP3A4, 1.7- to
3.2-fold for CYP2C9, and 3.0- to 5.0-fold for CYB2B6. Surpris-
ingly, CYP1A2 enzyme activity also increased (2.6- to 6.3-
fold) (Figure 5A). Luciferase assays revealed that dicloxacillin
activated PXR, but not CAR or AhR, in a dose-dependent
manner (Figure 6). Similar trends were seen for the chemi-
cally related isoxazolyl penicillin, ﬂucloxacillin (Figure 1),
with increases in the expression and activity of CYP3A4,
CYP2C9, CYP2B6 and CYP1A2 (Figures S5–S8). The induc-
tion of CYP enzymes by ﬂucloxacillin was less pronounced
than with dicloxacillin, which may have been caused by a
decrease in PXR activation by ﬂucloxacillin (Figure 6).
Discussion
The present study conﬁrmed the inductive potential of the
isoxazolyl penicillin, dicloxacillin, on the expression and ac-
tivity of drug-metabolizing CYP enzymes. CYP3A4-, CYP2C9-
and CYP2C19-mediated metabolismwere induced by 10 days
of treatment with 1 g dicloxacillin three times daily in a ﬁve-
Figure 5
Increased gene expression (A) and activity (B) of cytochrome P450
(CYP) 3A4, CYP2C9 and CYP2B6 caused by dicloxacillin treatment
of human hepatocytes (mean of four donors). Data are shown as
mean fold increase relative to vehicle (0.1% dimethyl sulfoxide)
with standard deviations. Solid and dashed lines represent
average (Css, avg), minimum (Css, min) and maximum concentration
of dicloxacillin (Css, max) at steady state at 500 mg dicloxacillin four
times daily in healthy volunteers [4]
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Figure 6
Nuclear receptor activity relative to vehicle induced by dicloxacillin
(A) and ﬂucloxacillin (B). AhR, aryl hydrocarbon receptor; CAR,
constitutive androstane receptor; PXR, pregnane X receptor. Data
are shown as mean fold-increase relative to vehicle (0.1%
dimethyl sulfoxide) with standard deviations. Solid and dashed lines
for dicloxacillin represent average (Css, avg), minimum (Css, min) and
maximum concentration of dicloxacillin (Css, max) at steady state at
500 mg dicloxacillin four times daily in healthy volunteers [4], while
the solid line for ﬂucloxacillin represents the maximum plasma
concentration after a 750 mg single dose of ﬂucloxacillin in healthy
volunteers [3]
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drug clinical pharmacokinetic study in healthy men. From
experiments in human hepatocytes, we showed that the
mechanism for this induction is likely to be PXR activation
leading to increased expression and activity of CYP enzymes,
and we hypothesize that this extends to ﬂucloxacillin.
The primary weakness of the study was the use of midazo-
lam as a buccal administration. This may lead to larger
variability in midazolam pharmacokinetics than intravenous
administration but the randomization procedure served to
minimize the impact of the within-subject variability of the
midazolam absorption proﬁle. While absolute bioavailability
following buccal administration in adults is about 75%, it is
not known how much undergoes intestinal absorption [35].
As CYP3A4 is highly expressed in both the liver and the intes-
tines, the increased midazolam metabolism observed in the
present study is likely to have been caused by a combination
of induction of hepatic enzymes and intestinal ﬁrst-pass
metabolism. In our study, we are unable to discriminate be-
tween intestinal and hepatic CYP3A4 induction. As we were
likely to have captured less effect on intestinal CYP3A4 activ-
ity, our results may reﬂect some conservative quantitative
bias. While not statistically signiﬁcant, the AUC ratio of mid-
azolam to metabolite did suggest a change but the precision
of the estimate was wide. AUC estimation of metabolite is
subject to several sources of bias, speciﬁcally with respect to
the proportion, variation and rate of renal elimination of
the glucuronidated metabolite, all of which affects metabo-
lite AUC. Quantiﬁcation of the amount of metabolite in the
urine following deglucuronidation is therefore more robust
and provides a better estimate of CLf and enzyme activity. A
minor weakness was the lack of protein analysis from the
in vitro study. However, as both mRNA expression and activity
of CYP enzymes were increased following dicloxacillin
exposure, it is likely that protein levels also increased.
The main strength of the study was the full pharmacoki-
netic proﬁles in the plasma and urine of ﬁve probe drugs
and their main metabolites. This allows pharmacokinetic
phenotyping of several CYP enzymes simultaneously, and
these extensive data provide an excellent overview of the
different metabolic pathways induced by dicloxacillin. The
clinical data from the present study are supported by in vitro
assessment in human hepatocytes, which is considered the
gold standard for in vitro assessment of alterations in drug
metabolism. Collectively, the in vivo and in vitro data strongly
support dicloxacillin being a clinically relevant inducer of
CYP3A4 and CYP2C metabolism.
The current results provide a mechanistic explanation for
our previous observation that dicloxacillin decreased INR
levels in patients receiving warfarin [14]. Dicloxacillin
activates PXR, causing increased expression of CYP2C9,
leading to increased CYP2C9-mediated metabolism of
warfarin and lower clinical efﬁcacy. CYP3A4 induction may
be of signiﬁcance as well, as the metabolism of the warfarin
R-enantiomer, a less potent inhibitor of vitamin K epoxide
reductase [36], is catalysed by CYP3A4 [37]. These results are
also in line with previous in vitro data indicating that
dicloxacillin is a CYP3A4 inducer [17]. We showed a similar
extent of induction of probe substrate metabolism for
CYP3A4, and also CYP2C9.
Both omeprazole AUC0–24 h and Cmax were signiﬁcantly
reduced after dicloxacillin exposure, although CLf for the
5-hydroxymetabolite was unchanged. This was likely to have
been caused by one outlier with a large reduction in CLf
(threefold) after dicloxacillin exposure (Figure 4). This is in
stark contrast to the increased CLf observed for the majority
of other subjects (two of the other 11 individuals had minor
reductions in CLf after dicloxacillin exposure; Figure 4). Inter-
estingly, we showed that dicloxacillin also decreased the
AUC0–24 h of dextromethorphan. Besides CYP2D6, CYP3A4
also catalyses the metabolism of dextromethorphan [38]. As
CYP2D6 is not thought to be signiﬁcantly inducible and the
CLf of dextrorphan is unchanged, the observed effect on
dextromethorphan pharmacokinetics is likely to have been
caused by induction of 3-methoxymorphinan formation by
CYP3A4. Caffeine AUC0–24 h is also affected but no change
in CLf was observed. CYP1A2 is responsible for around 95%
of the primary metabolism of caffeine but CYP3A4, CYP2C8
and CYP2C9 may also be involved in the metabolism [39].
It is plausible that induction of these enzymes may lead to
the marginally increased caffeine metabolism that we
observed. The present study did not assess the length of the
observed induction after conclusion of dicloxacillin treat-
ment. A previous study showed that 7 days of treatment with
rifampicin produced enzyme induction, but the induced
activities were no longer detectable 8 days after conclusion
of rifampicin treatment [40]. Another clinical study showed
that the inductive effect of rifampicin on CYP3A4 persisted
for about 4 weeks following 28 days of treatment [41].
Owing to the brevity of the exposure to dicloxacillin
(the standard treatment duration is 7–10 days), CYP induc-
tion is not expected to be of substantial clinical signiﬁcance
for a large proportion of widely used drugs. The clinical
efﬁcacy of many drugs, such as cholesterol-lowering agents,
is largely a result of long-term treatment, and 10 days of
induction should not have a substantial impact on the overall
therapeutic efﬁcacy. However, the clinical efﬁcacy of drugs
with a narrow therapeutic range, such as antiepileptic agents
or immunosuppressants, may be affected by concomitant
dicloxacillin treatment. Penicillins were previously suspected
of causing therapeutic failure of oral contraceptives [42] but a
potential mechanism for this observation was never identi-
ﬁed, and no solid evidence has substantiated the existence
of these putative drug–drug interactions. Owing to the
substantial induction of CYP3A4 by dicloxacillin, it is plausi-
ble that concomitant use of dicloxacillin and oral contracep-
tives increases the metabolism of the latter, and may lead to a
risk of therapeutic failure and unwanted pregnancy. This pu-
tative drug–drug interaction warrants properly designed
pharmacokinetic studies to determine its magnitude and
clinical relevance.
Our in vitro results lend credence to a hypothesis that
treatment with the chemically related drug, ﬂucloxacillin
(Figure 1), more widely used in the UK [43, 44], may induce
CYP enzymes, although possibly to a lesser extent than
dicloxacillin. Induction of CYPs by ﬂucloxacillin should be
quantiﬁed by an adequately designed in vivo pharmacoki-
netic drug–drug interaction study to guide recommendations
for the use of these isoxazolyl penicillins. We also showed
that dicloxacillin induces CYP2B6 expression and activity.
Whether this translates to changes in the clinical pharmaco-
kinetics of CYP2B6 substrates needs to be elucidated, and is
especially relevant for antiretroviral drugs such as efavirenz.
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In conclusion, dicloxacillin is an inducer of CYP3A4- and
CYP2C-mediated metabolism in healthy volunteers and in
human hepatocytes. The effect is clinically relevant, and we
recommend caution when prescribing dicloxacillin to users
of drugs with a narrow therapeutic window that are metabo-
lized by CYP2C9, CYP2C19 or CYP3A4.
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